Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 196

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 196
---
31, 2025, we and our Chief Executive Officer entered an amendment to the December 2024 Loan
Agreement to extend the maturity date until the earlier of August 31, 2025, or the consummation of an IPO.

In April 2025, we entered
into bridge loan agreements, or the 2025 Loan Agreements, pursuant to which we obtained bridge loans in the aggregate amount of $200,000
from certain lenders, including Dr. Ehud Geller, the chairman and a member of the board of directors, and Pini Ben Elazar, a director
nominee. The loans pursuant to the 2025 Loan Agreements bear interest at a rate of 8% per annum until maturity. Pursuant to the terms
of the 2025 Loan Agreements, we also agreed to pay the lenders an additional risk premium equal to 50% of their respective loan amount.
The loans under the 2025 Loan Agreements mature upon the earlier of August 31, 2025 or the date of consummation of a Qualified IPO
(as such term is defined in the 2025 Loan Agreements). Furthermore, upon the occurrence of a Qualifying IPO, the Bridge Loan lenders,
shall be granted warrants to purchase such number of Ordinary Shares equal to two times their respective loan amount in addition to a
risk premium based on a price per share equal to 75% of the lowest price per share of the Ordinary Shares during the first five trading
days following the consummation of such Qualifying IPO.

Agreements and Arrangements With, and Compensation of, Directors and Executive Officers

All
of our executive officers have employment or consultancy agreements with us which contain customary provisions and representations, including confidentiality, non-competition, non-solicitation and inventions assignment
undertakings by the executive officers. None of our
employment or service provider agreements contain any terms providing for severance benefits.
Under current applicable Israeli employment laws, we may not be able to enforce (either in
whole or in part) covenants not to compete and therefore may be unable to prevent our competitors
from benefiting from the expertise of some of our former employees. See “Management—Compensation
of Executive Officers and Directors”. In addition, certain of our other executive officers
have service provider agreements with us pursuant to which they are engaged by us as independent
contractors. These service provider agreements prohibit such executive officers from engaging
in activities that would present a conflict of interest to